drugset
drugset / Trial / NCT03856619

To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis

NCT03856619 ↗

Phase 4 Completed 121 enrolled Sanofi
NaSingle-groupOpen-labelTreatment

Summary

Primary Objective: To describe the safety of teriflunomide in patients with relapsing forms of multiple sclerosis. Secondary Objective: To describe the efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis.

Timeline

Start
2019-03-27
Primary completion
2022-05-13
Completion
2022-05-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriflunomide Small molecule — Oral

Indications

multiple sclerosis